Artelo Biosciences, Inc. (NASDAQ:ARTL) Given Average Rating of “Hold” by Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have earned a consensus recommendation of “Hold” from the five research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.00.

A number of equities analysts have recently issued reports on ARTL shares. D. Boral Capital restated a “hold” rating on shares of Artelo Biosciences in a research note on Monday, September 8th. D Boral Capital cut shares of Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a research report on Saturday, September 27th. Finally, Wall Street Zen cut shares of Artelo Biosciences to a “strong sell” rating in a research report on Saturday, August 9th.

Artelo Biosciences Stock Performance

Shares of ARTL stock opened at $4.69 on Friday. Artelo Biosciences has a 52-week low of $4.20 and a 52-week high of $28.60. The stock has a market cap of $3.28 million, a price-to-earnings ratio of -0.25 and a beta of 1.41. The firm has a fifty day moving average of $7.81 and a 200-day moving average of $7.95.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($5.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($5.48). On average, sell-side analysts predict that Artelo Biosciences will post -2.62 earnings per share for the current year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.